ImmunologybioRxiv
Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma
DOI 10.1002/hep.32279
Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
1 paper
Recent·Most cited